Scholarlink

<p>Platinum-based chemotherapy was the mainstay of treatment for advanced urothelial carcinoma (UC) for decades, but the therapeutic landscape has fundamentally changed. Immune checkpoint blockade showed overall survival (OS) benefit in phase&#xa0;3&#xa0;trials: as second line (pembrolizumab), as maintenance therapy (avelumab) following frontline chemotherapy response, or in combination with cisplatin-chemotherapy (nivolumab). Options after failure to chemo- and immunotherapy consist of enfortumab vedotin (EV) or erdafitinib (in case of <i>FGFR3</i> mutations). However, the most significant change was the superiority of EV plus pembrolizumab over chemotherapy in the EV302 trial, which has become the new standard frontline therapy. In the peri-operative setting, anti-PD-(L)1 has shown benefit as adjuvant therapy (nivolumab and pembrolizumab; not yet for OS) and in the peri-operative setting, combined with chemotherapy (durvalumab; including OS).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systemic therapy for urothelial cancer: platinum defeated?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Chantal F. Stockem,
  • Michiel S. van der Heijden

摘要

Platinum-based chemotherapy was the mainstay of treatment for advanced urothelial carcinoma (UC) for decades, but the therapeutic landscape has fundamentally changed. Immune checkpoint blockade showed overall survival (OS) benefit in phase 3 trials: as second line (pembrolizumab), as maintenance therapy (avelumab) following frontline chemotherapy response, or in combination with cisplatin-chemotherapy (nivolumab). Options after failure to chemo- and immunotherapy consist of enfortumab vedotin (EV) or erdafitinib (in case of FGFR3 mutations). However, the most significant change was the superiority of EV plus pembrolizumab over chemotherapy in the EV302 trial, which has become the new standard frontline therapy. In the peri-operative setting, anti-PD-(L)1 has shown benefit as adjuvant therapy (nivolumab and pembrolizumab; not yet for OS) and in the peri-operative setting, combined with chemotherapy (durvalumab; including OS).